Form 4 for EWTX Edgewise Therapeutics, Inc.
Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-01 · accession 0001562180-24-003829 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-03 | 2024-05-01 | EWTX | Carruthers R Michael | CFO | M - OptEx | $0.00 | +5,208 | 37.4K | +16% | $0 |
| D | 2024-05-03 | 2024-05-02 | EWTX | Carruthers R Michael | CFO | S - Sale+OE | $18.91 | -2,157 | 35.2K | -6% | -$40.8K |
| D | 2024-05-03 | 2024-05-01 | EWTX | Carruthers R Michael | CFO | M - OptEx | $0.00 | -5,208 | 5,209 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-01 | M | A | 5,208 | $0.00 | 37,387 | D | — | — | (F1) Includes 2,898 shares purchased on May 15, 2023 and 257 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-05-02 | S | D | 2,157 | $18.91 | 35,230 | D | — | — | (F3) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Restricted Stock Units | 2024-05-01 | M | D | 5,208 | $0.00 | 5,209 | D | $0.00 · — to 2032-05-01 | 5,208 Common Stock | (F4) RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. |